• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Invitae | Genelex

Invitae | Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • For Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
  • For Providers
    • Conditions
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • Contact Us
  • Log In
Home / Test Menu / HLA-A or HLA-B

HLA-A and HLA-B Genotyping

HLA-A or HLA-B GenotypingHLA-A and HLA-B (major histocompatibility complex, class I, A, and B) are closely related proteins in the human leukocyte antigen (HLA) complex. They play major roles in the immune system and are found on nearly every cell.

Carriers of certain polymorphisms, such as HLA-A*31:01, HLA-B*15:02, HLA-B*57:01 rs2395029 (LD), and HLA-B*58:01, are at risk for severe hypersensitivity when given certain medications, including abacavir (Ziagen®), allopurinol (Zyloprim®), phenytoin (Dilantin®), and carbamazepine (Tegretol®).

These medications are typically used as part of treatments for epilepsy, bipolar disorder, gout, and HIV.[50]

Indications for HLA-A and HLA-B Testing

Testing prior to initiating commonly impacted drugs helps to identify patients at high risk for severe drug-induced hypersensitivity reactions. Testing should be considered for individuals with a personal or family history of adverse drug effects to abacavir (Ziagen®), allopurinol (Zyloprim®), and carbamazepine (Tegretol®). Testing should be done to confirm the presence of genotypes that affect the sensitivity to specific medications.

Patients initiating carbamazepine therapy may benefit from HLA-A*3101 testing. All patients of Asian ethnicity should be tested for the HLA-B*15:02 allele prior to phenytoin (Dilantin®), and carbamazepine (Tegretol®).  and fosphenytoin (Cerebyx®) administration. Patients of all ethnicities should be tested for HLA-B*57:01 rs2395029 (LD) prior to abacavir administration due to incidence of hypersensitivity. All patients should be tested for HLA-B*58:01 prior to allopurinol therapy due to severe cutaneous reactions.[51] Assessment of medical necessity for testing is up to the provider’s clinical judgment.

Insurance Coverage, Special Order

HLA-B*57:01 rs2395029 (LD) testing may be covered by private insurance providers (CPT code 81381, provided as guidance only). HLA-A*31:01, HLA-B*15:02, and HLA-B*58:01 are only available as special order projects (contact us for pricing).

Specimen Collection

Click here to order testing supplies or call Client Services at 800-837-8362

  • Buccal Swabs: 4 sterile buccal swabs
  • Blood: 5-10cc whole blood lavender-top EDTA or yellow-top ACD-A tubes
  • Turnaround Time: 10 business days, faster turnaround available for clinical trials

Individual Genes Tested

CYP2C9
CYP2C19
CYP2D6
CYP3A4 / CYP3A5
ADRA2A
CYP1A2
CYP2B6
CYP4F2 / VKORC1
COMT
DPYD
Factor II - Factor V Leiden
GRIK4
HLA-A or HLA-B
HTR2A
HTR2C
IFNL3
MTHFR
NAT2
OPRM1
SLCO1B1
TPMT
UGT1A1

Improving Drug Efficacy

Genelex's pharmacogenetic testing bridges the gap in understanding how the role of PGx can help in patient care and offers a simple DNA test and provides you with a report of the results that you and your doctor can discuss.

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
FAQs
References

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Contact Us
Privacy Practices
Privacy Policy

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.